

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT

APPOINTMENT OF CHIEF COMMERCIAL OFFICER

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce the appointment of Mr. Kevin Guo (郭 永) (“**Mr. Guo**”) as Chief Commercial Officer of the Company.

The biographical details of Mr. Guo are set out below:

Mr. Guo has more than 22 years of commercial leadership and business management experience across a number of multinational pharmaceutical companies. Mr. Guo joins the Company after holding leadership positions at Eisai, where he most recently served as vice president and deputy global brand lead for LENVIMA, driving the development and execution of global product launch strategies, including in markets such as China, Japan and other Asia regions. Prior to this, he was vice president and head of the pharmaceutical business division of Eisai China Inc., where he managed several key business functions and was also appointed as chairman of the Board and president of Eisai (Suzhou) Trading Co., Ltd. In addition, Mr. Guo was the vice president of Oncology Business Unit 1 in Shanghai Roche Pharmaceutical Ltd., among other key commercial and business development positions at prominent global pharmaceutical companies, including GlaxoSmithKline plc, Wyeth Pharmaceutical Co., Ltd. (now part of Pfizer Inc.), Sino-American Shanghai Squibb Pharmaceutical Limited and Eli Lilly Asia Inc.. Mr. Guo obtained his Bachelor’s degree in clinical medicine from Fourth Military University in China and his Executive MBA from China Europe International Business School.

The Board would like to express its warmest welcome to Mr. Guo on his appointment.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, February 18, 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.